Integrative Chiropractic Care: A Comprehensive Guide for Insomnia

Learn how integrative chiropractic care for insomnia can benefit your overall health and help you achieve restful sleep.

Abstract

As a clinician holding DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST credentials, I present an educational exploration of insomnia care grounded in modern, evidence-based research and real-world clinical integration. This post describes how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas—where Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933) serves as Medical Director and Collaborative Physician—blends medical oversight with chiropractic care, functional medicine, personal injury rehabilitation, and cognitive-behavioral strategies. I will walk you through a practical decision framework, detailed physiology of sleep regulation, and two complex case scenarios translating research into care: a 57-year-old male with insomnia and a past alcohol use disorder; and a 70-year-old female with chronic insomnia, mild cognitive impairment, osteoporosis, and dermatologic comorbidity. Along the way, I explain the rationale for low-risk hypnotics (e.g., doxepin, ramelteon, dual orexin receptor antagonists), when and how to escalate or switch agents, how to identify and treat sleep apnea risk, and how integrative chiropractic care can holistically address pain, autonomic dysregulation, circadian misalignment, and neuroinflammation to support sleep maintenance and restorative function. I also outline a shared decision-making model, tapering strategies, and team-based care pathways. Citations include leading sleep medicine and neurobiology sources, and I highlight how we adapt these insights to patient-centered plans, including when treatment resistance demands advanced consultation and careful, mechanism-based polypharmacy.

Introduction: My Approach to Insomnia as an Integrative Clinician

I have the privilege of practicing at the intersection of chiropractic medicine, advanced practice nursing, and functional medicine. Insomnia is one of the most challenging and rewarding conditions we treat because it touches nearly every physiologic system—from neurochemical signaling and autonomic tone to metabolic health, pain processing, and immune function. My approach is to assess the whole person, align interventions with the foundational physiology of sleep, and integrate care within a coordinated team.

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, I work closely with Dr. Maria Guadalupe Cardenas, MD, a Board-Certified Internist with over 40 years of experience who serves as our Medical Director and Collaborative Physician. Her oversight ensures that medical comorbidities, safety profiles, and pharmacologic considerations are thoroughly reviewed. At the same time, I deliver chiropractic and functional medicine interventions directed at musculoskeletal contributors, autonomic balance, and lifestyle factors that reinforce healthy sleep architecture. In complex situations—personal injury, chronic pain, metabolic dysfunction, mental health considerations—we build a shared plan that is safe, individualized, and evidence-guided.

In this educational post, I will:

• Explain the physiology of sleep regulation, including circadian and homeostatic systems, neurochemistry of arousal and inhibition, and the role of the orexin system.
• Provide a structured assessment and treatment framework, including the identification of insomnia subtypes, risk factors, and comorbidities such as obstructive sleep apnea (OSA), depression/anxiety, pain, and dermatologic conditions.
• Present two case applications and explain the logic behind selecting doxepin, ramelteon, or a dual orexin receptor antagonist (DORA), and when to adjust dosing or switch mechanisms.
• Describe how we integrate chiropractic adjustments, myofascial care, rehabilitation, autonomic regulation, and functional medicine (nutrition, inflammation control, circadian entrainment) with medical oversight.
• Clarify shared decision-making, safety checks for vulnerable populations, tapering strategies, and referral thresholds.
• Discuss what we do in treatment-resistant insomnia, including mechanism-based polypharmacy only under advanced oversight.

Throughout, I will highlight key terms in bold and connect each recommendation to its rationale, so you can see both what we do and why we do it.

Our Multidisciplinary Model in El Paso: How We Coordinate Care

At our clinic, integrative care is not a slogan; it is a workflow. Here is how we coordinate insomnia care:

• Medical Direction and Safety Oversight (Dr. Maria Guadalupe Cardenas, MD)

• Reviews medical history, medications, and comorbidities (e.g., hypertension, obesity, cognitive impairment) that shape insomnia management.
• Screens for and co-manages conditions such as obstructive sleep apnea, restless legs syndrome, thyroid dysfunction, dermatologic disease, depression/anxiety, and cardiometabolic risk.
• Guides pharmacotherapy choices (e.g., low-dose doxepin, ramelteon, DORAs), dosing strategies, and tapering plans, with careful attention to sex- and age-specific pharmacokinetics in older adults.
• Coordinates diagnostics (labs, sleep studies) and referrals to sleep medicine, psychiatry, dermatology, or other specialists.

• Chiropractic and Functional Rehabilitation (Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST)

• Targets nociceptive and mechanosensory drivers of nocturnal arousal through spinal manipulation, soft-tissue therapy, joint mobilization, and neuromuscular re-education to reduce pain signaling that fragments sleep.
• Applies rehabilitation protocols to normalize movement patterns and decrease evening pain spikes that sabotage sleep onset and maintenance.
• Implements autonomic regulation techniques to shift toward parasympathetic dominance in the evening: breathwork, biofeedback-informed pacing, vagal maneuvers, and graded activity timing.
• Aligns circadian cues through light hygiene, temperature strategies, meal timing, and exercise scheduling that supports endogenous melatonin and sleep drive.

• Functional Medicine Integration

• Assesses and modulates inflammatory tone (e.g., CRP, dietary triggers), metabolic status (glycemic variability), and micronutrients relevant to sleep regulation (e.g., iron for RLS screening, vitamin D, magnesium).
• Evaluates gut-skin-immune axes when dermatologic symptoms disrupt sleep; coordinates anti-pruritic strategies, barrier support, and allergen elimination if indicated.
• Builds lifestyle protocols for sleep hygiene, stimulus control, and CBT-I adherence, with practical tracking and accountability.

• Personal Injury and Pain Considerations

• In injury populations, pain often drives conditioned arousal and sleep fragmentation. We coordinate analgesic timing, rehabilitation dosing, and pre-sleep downregulation to decouple pain-triggered hyperarousal.

• Documentation and Team Communication

• We employ standardized sleep questionnaires (e.g., ISI), sleep diaries, the Epworth Sleepiness Scale when OSA is suspected, and structured checklists. Care plans are shared with patients and across the team for transparency and continuity.

The Physiology of Sleep: Why Our Interventions Work

To build a treatment plan that matches the patient, we first map the physiology:

• The Two-Process Model

• Process C (Circadian): The suprachiasmatic nucleus (SCN) sets daily rhythms for hormone release, core body temperature, and alertness. Exposure to blue-enriched light in the evening suppresses melatonin, delaying sleep onset. Morning bright light anchors the circadian phase (Czeisler & Gooley, 2007).
• Process S (Homeostatic Sleep Drive): Accumulation of adenosine during wakefulness raises sleep pressure; sleep clears adenosine. Caffeine blocks adenosine receptors, reducing perceived sleepiness. Daytime napping dissipates Process S, making nighttime sleep harder (Porkka-Heiskanen et al., 1997).

• Neurochemistry of Wake and Sleep

• Wake systems: Orexin/hypocretin (lateral hypothalamus) stabilizes wakefulness and fosters arousal; norepinephrine (locus coeruleus), histamine (tuberomammillary nucleus), dopamine, serotonin, and acetylcholine are integral (Saper et al., 2001; Sakurai, 2007).
• Sleep systems: GABA from the ventrolateral preoptic nucleus inhibits wake-promoting centers; melatonin from the pineal gland signals biologic night; adenosine promotes sleepiness (Arendt, 1998; Porkka-Heiskanen et al., 1997).
• The flip-flop switch: Mutual inhibition between sleep and wake centers creates stable states. Hyperarousal (stress, pain, anxiety, medications) destabilizes the switch, causing frequent transitions and awakenings.

• The Orexin Axis and DORAs

• Orexin maintains wake stability; excessive orexin tone contributes to sleep maintenance insomnia and difficulty turning off arousal. Dual orexin receptor antagonists (DORAs) reduce orexin signaling, promoting sustained sleep with less psychomotor impairment than some GABAergic hypnotics, and tend to preserve sleep architecture more physiologically (Sakurai, 2007; Sateia et al., 2017).

• Pain, Autonomic Tone, and Sleep

• Pain amplifies sympathetic output, elevates cortical arousal, and drives micro-awakenings. Chiropractic interventions that decrease nociceptive input can reduce sympathetic dominance and foster deeper sleep.
• Evening autonomic balance is crucial: Parasympathetic predominance supports sleep initiation and maintenance; breathwork and gentle myofascial release before bed can help shift this balance.

• Inflammation and Neuroimmune Interactions

• Pro-inflammatory cytokines (IL-6, TNF-α) alter REM/NREM architecture and increase fatigue but paradoxically fragment sleep. Diet, weight management, and targeted anti-inflammatory strategies can reduce this burden (Irwin, 2019; Besedovsky et al., 2012).

• Dermatologic Disruption and the Itch-Scratch Cycle

• Nocturnal pruritus increases arousals and impairs slow-wave sleep. Barrier repair, anti-pruritic treatment, and temperature optimization can restore sleep continuity.

• Aging, Sex Differences, and Pharmacokinetics

• Age reduces slow-wave sleep and alters drug metabolism; older adults are more sensitive to hypnotic adverse effects and falls. Women may require lower starting doses due to pharmacokinetic differences with certain medications (e.g., zolpidem) (BMJ sources; Hirshkowitz et al., 2015).

Assessment Framework: Building a 360-Degree View

When I evaluate insomnia, I gather the following:

• Sleep History

• Onset vs maintenance vs mixed insomnia; sleep schedule, latency, wake after sleep onset (WASO), total sleep time, naps, sleep environment.
• Previous treatments (behavioral and pharmacologic), responses, and adverse effects.

• Sleep Hygiene and Behavioral Patterns

• Evening light exposure, screen use, caffeine and alcohol timing, exercise timing, pre-sleep routine, stimulus control compliance.

• Daytime Function and Safety

• Next-day sleepiness, near-misses or falls, cognitive difficulties, mood, functional capacity.

• Medical and Psychiatric Comorbidities

• Depression, anxiety, chronic pain, cardiometabolic disease, dermatologic conditions, reflux, thyroid, perimenopause/menopause, BPH and nocturia, MCI, neurodegenerative disorders.

• Medication/Substance Review

• Stimulants, activating antidepressants, steroids, SNRIs at night, beta-blockers, decongestants, nicotine, alcohol. Supplements used and their effects.

• OSA and Sleep-Disordered Breathing Risk

• Snoring, witnessed apneas, gasping awakenings, morning headaches, obesity, neck circumference, refractory insomnia. Consider STOP-Bang screen and referral for sleep testing.

• Physical and Neurologic Exam

• Pain generators, joint restrictions, myofascial tenderness, postural dysfunction, airway evaluation, autonomic markers (HR/BP variability), dermatologic assessment.

• Objective Tracking

• Sleep diaries for at least 2 weeks; optional actigraphy; baseline ISI score; Epworth score when daytime sleepiness is prominent.

Balancing Body and Metabolism- Video

Treatment Principles: Mechanism, Safety, and Personalization

I organize care into layered components:

• Foundational Nonpharmacologic Strategies

• CBT-I as first-line: stimulus control, sleep restriction, cognitive restructuring, relaxation training, and sleep hygiene. This yields durable benefit and should be offered whenever possible (Trauer et al., 2015; Morin & Benca, 2012).
• Circadian synchronization: consistent wake time, morning bright light, minimal evening blue light, melatonin timing when indicated (Czeisler & Gooley, 2007; Arendt, 1998).
• Autonomic downregulation: slow diaphragmatic breathing, paced exhalation, progressive muscle relaxation, gentle mobility and myofascial release.

• Integrative Chiropractic and Rehabilitation

• Spinal manipulation and soft-tissue mobilization reduce nociceptive input, lower sympathetic tone, and may improve sleep continuity.
• Movement therapy: timing exercise earlier in the day for sleep onset issues; if pain is the driver, carefully titrated evening mobility to prevent nocturnal flare.
• Postural and ergonomic optimization, especially for those with cervical or lumbar pain that awakens them at night.

• Functional Medicine and Lifestyle

• Anti-inflammatory nutrition: emphasis on whole foods, omega-3s, reduced refined sugars; identify triggers (e.g., histamine, gluten) when relevant.
• Metabolic stability: address nocturnal hypoglycemia or reflux; align meal timing.
• Micronutrient checks when clinically indicated (e.g., iron for RLS; vitamin D; magnesium).

• Pharmacologic Options with Rationale

• Low-dose doxepin: selective H1 antagonism at low doses improves sleep maintenance with minimal anticholinergic effects; useful for nocturnal awakenings and older adults when carefully dosed.
• Ramelteon: MT1/MT2 melatonin receptor agonist that promotes sleep onset and circadian alignment; no abuse potential, helpful for those avoiding controlled substances.
• Dual orexin receptor antagonists (DORAs): target orexin-mediated wakefulness; improve maintenance with a favorable cognitive and fall-risk profile relative to some GABAergic agents (Sateia et al., 2017; Krystal, 2019).
• Z-drugs (e.g., zolpidem): effective for onset/maintenance but carry risks (complex sleep behaviors, tolerance, falls); lower doses in women and older adults, and careful monitoring are essential.
• Benzodiazepines: generally avoided in older adults and those with cognitive vulnerability due to risks of dependence, cognitive impairment, and falls; reserve for specific indications with strict oversight.

• Safety and Monitoring

• Start low, go slow, and reassess within 1–2 weeks.
• Avoid polypharmacy unless treatment-resistant cases under advanced supervision; monitor for tolerance, misuse, and adverse events.
• Coordinate with sleep medicine when OSA is suspected, or insomnia is refractory.

Case Application 1: A 57-Year-Old Male with Insomnia and Past Alcohol Use Disorder

Clinical snapshot

• History: Depression, anxiety, hypertension, obesity, past alcohol use disorder (sober >15 years), adherent to medications, attends AA and individual therapy.
• Current issue: Insomnia more than half the week for several months, difficulty with sleep onset and maintenance; OTC melatonin not effective.
• Concern: Wishes to avoid controlled substances due to addiction history.

Assessment considerations

• Sleep hygiene: Evening screens? Caffeine timing? Inconsistent schedule? Bedroom environment?
• Next-day effects: Drowsiness, functional impairment, safety concerns.
• Comorbid risks: Obesity and age raise suspicion for OSA—snoring, witnessed apneas, morning headaches, nocturnal choking?
• Psychiatric factors: Depression and anxiety reportedly controlled, but subtle hyperarousal patterns may persist.
• Medication review: Any activating agents at night? Alcohol abstinence maintained? Interactions with antihypertensives?
• Patient preference: Explicitly avoid controlled substances.

Plan and rationale

• Nonpharmacologic foundation

• Initiate CBT-I emphasizing stimulus control and sleep restriction to consolidate sleep. Clearly define bed and wake times; remove screens; encourage getting out of bed if awake >20 minutes and performing a calm activity until drowsy.
• Circadian support: Morning bright light within 60 minutes of waking; minimize evening blue light; anchor wake time.
• Autonomic regulation: Evening breathwork (e.g., 4-7-8 or 6 breaths/min), progressive muscle relaxation, and gentle mobility to reduce hyperarousal.

• Chiropractic and rehabilitation integration

• Evaluate for pain generators that may worsen nocturnal arousals; apply targeted spinal manipulation and myofascial release where indicated to reduce sympathetic tone and pain spikes.
• Introduce earlier-day exercise; avoid high-intensity workouts within 3–4 hours of bedtime.

• Functional medicine alignment

• Screen inflammatory markers and metabolic stability if clinically relevant; adjust nutrition to reduce nighttime reflux or glycemic swings; limit late meals and alcohol (maintained abstinence).

• Pharmacologic options aligned with preferences

• First-line: Ramelteon for sleep onset and circadian signaling; low risk for dependence and minimal next-day effects (JAMA trials; Arendt, 1998).
• Alternative or adjunct: Low-dose doxepin for sleep maintenance if awakenings persist; start at the low end and titrate cautiously (Sateia et al., 2017).
• Consider DORA if maintenance remains problematic and if patient is open to a controlled medication with a low abuse profile. DORAs have substantially lower risk of tolerance and dependence than benzodiazepines or Z-drugs and can be a pragmatic option when noncontrolled agents are insufficient (Krystal, 2019).

• OSA consideration

• Given obesity and age, refer to sleep medicine for diagnostic evaluation if screening suggests risk or if insomnia remains refractory despite good adherence.

• Follow-up and escalation

• Reassess in 2–4 weeks; if onset remains problematic despite ramelteon, confirm timing, reinforce stimulus control, and consider adding doxepin or switching to a DORA to target maintenance.
• If pharmacologic adjustment fails, consult sleep specialist and consider actigraphy-guided phase assessment.

Why this works

• We align interventions with thepatient’ss preference to avoid dependence risks, leverage melatonin receptor agonism for onset, H1 antagonism at low doxepin doses for maintenance, and reserve DORAs as a next step for consolidation without GABAergic side effects. Chiropractic and autonomic strategies reduce hyperarousal and pain-related awakenings, while CBT-I consolidates sleep drive.

Case Application 2: A 70-Year-Old Female with Chronic Insomnia, MCI, Depression, Eczema, and Osteoporosis

Clinical snapshot

• History: Chronic insomnia, mild cognitive impairment (MCI), recurrent depression, atopic dermatitis, osteoporosis.
• Current medication: Zolpidem 5 mg initially effective but now ineffective; can fall asleep but awakens 3–4 hours later and struggles to return to sleep.
• Behavior: Naps 2–3 hours in daytime; often watches TV when unable to sleep.
• Symptom aggravator: Worsening eczema impairs comfort.

Assessment considerations

• Safety: Older adult, female, MCI, osteoporosis—high risk for falls and cognitive side effects from sedative-hypnotics.
• Sleep pattern: Maintenance insomnia with long naps disrupting homeostatic sleep drive; nocturnal awakenings reinforced by TV.
• Dermatologic burden: Itch-scratch cycle disrupting sleep continuity.
• Depression control: Evaluate current status; depression can worsen insomnia and vice versa.
• Medication issues: Zolpidem tolerance and dose escalation risk; higher doses in women and older adults increase adverse events.

Plan and rationale

• Nonpharmacologic and behavioral reset

• Strict CBT-I: eliminate long daytime naps; institute sleep restriction to rebuild Process S; remove TV from bedroom and implement stimulus control; use a consistent wake time (Trauer et al., 2015).
• Educate on getting out of bed during awakenings for a calm activity until drowsy; avoid clock watching.

• Dermatology integration

• Treat eczema aggressively to reduce nocturnal pruritus—optimize emollients, barrier repair, nighttime topical anti-inflammatory therapy per dermatologic guidance, and consider bedroom temperature and humidity control.

• Chiropractic and rehabilitation integration

• Assess cervicothoracic and lumbopelvic contributors to nocturnal discomfort; gentle manual therapy to reduce arousals from pain. For osteoporosis, use modified techniques avoiding high-velocity thrusts where contraindicated; emphasize soft-tissue, low-force mobilization, and positioning for comfort.

• Pharmacologic adjustments with safety priority

• Switch from zolpidem 5 mg to a dual orexin receptor antagonist (DORA) to improve maintenance with a safer cognitive and fall-risk profile in older adults and better alignment with MCI (Krystal, 2019).
• If a DORA is not immediately available or affordable, consider zolpidem controlled release 6.25 mg as a temporary step for maintenance while minimizing dose escalation, acknowledging the elevated risk profile and monitoring closely.
• Avoid benzodiazepines given falls, cognitive impairment, and osteoporosis fracture risk.

• Depression and cognition

• Coordinate with primary care/psychiatry to ensure depression is optimally treated; avoid activating antidepressants at night; consider shifting dosing to morning.

• Follow-up and escalation

• Reassess within 2–3 weeks; measure falls risk, cognition, and daytime alertness. If response is partial, adjust DORA timing and ensure strict adherence to CBT-I. For persistent issues, consult sleep medicine, especially to exclude comorbid sleep-disordered breathing.

Why this works

• DORAs address maintenance insomnia by modulating orexin without profound psychomotor impairment. Removing long naps restores homeostatic pressure; eliminating nighttime TV reduces conditioned arousal. Treating eczema directly removes a physiologic disruptor. Modified chiropractic care improves comfort without compromising bone health.

Shared Decision-Making: Aligning Care with Patient Values

• Present options in plain language with risks, benefits, and alternatives.
• Incorporate preferences such as avoiding controlled substances or minimizing morning grogginess.
• Set clear expectations for timelines: CBT-I benefits often become robust after several weeks; pharmacologic changes may show earlier effects but need monitoring.
• Use sleep diaries to evaluate progress and adjust the plan jointly.

When Treatment Doesn’t Work: Dose, Switch, Consult

• Stepwise approach

• Gradual dose increases within recommended ranges when safe.
• Switch to an agent with a different mechanism of action (e.g., from doxepin to ramelteon, or to a DORA) if ineffective.
• Refer to sleep medicine or mental health for refractory cases.

• Long-term management

• Monitor for tolerance, dependence, and complex sleep behaviors, especially with Z-drugs and benzodiazepines.
• Continue reinforcing sleep hygiene and CBT-I principles at every visit; repetition supports behavior change.
• Taper hypnotics gradually when discontinuing unless a severe adverse reaction (e.g., complex sleep behavior, confusion) mandates abrupt cessation with safety planning.

• Treatment-resistant insomnia

• Consider carefully supervised, mechanism-based polypharmacy only in advanced settings and with robust patient-provider alliance and informed consent.
• Maintain interprofessional collaboration—primary care, internal medicine, psychiatry, sleep medicine, dermatology, and rehabilitation—to cover all modifiable drivers.

How Integrative Chiropractic Care Fits: Mechanisms and Methods

Chiropractic care is not a sedative, nor is it a substitute for CBT-I or medical therapy. Its role is to relieve physiologic barriers to sleep and support the neurobiological conditions in which natural sleep can occur.

• Pain modulation

• By reducing nociceptive drive, spinal manipulation and myofascial techniques can diminish nocturnal arousals and WASO.

• Autonomic balance

• Manual therapy may facilitate parasympathetic activation, lowering heart rate and blood pressure variability in the evening and reducing hyperarousal.

• Sensorimotor recalibration

• Improving joint mechanics and muscle tone reduces discomfort in prolonged positions at night.

• Breath and posture

• Thoracic mobility and diaphragmatic mechanics affect CO2 sensitivity and respiratory ease, which can ease transitions into sleep.

• Clinical observations

• In my practice and documented through my professional reflections and writings, consistent, gentle evening treatment sequences—breath training, low-force mobilization, and pre-sleep micro-mobility drills—have been associated with improved subjective sleep quality in patients with musculoskeletal contributors.

Teamwork in Action: Roles and Responsibilities

• Dr. Cardenas, MD (Medical Director)

• Ensures safety, addresses comorbidities, manages medications, orders and interprets sleep studies, and coordinates specialty referrals.

• Dr. Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

• Leads integrative chiropractic and functional medicine interventions, designs rehabilitation and autonomic programs, and integrates behavior change strategies.

• Behavioral health and therapy partners

• Provide CBT-I and psychotherapy, collaborating on stimulus control and cognitive restructuring.

• Sleep medicine colleagues

• Evaluate for sleep apnea, movement disorders, circadian rhythm disorders, and offer advanced interventions when needed.

Practical Tools You Can Use Now

• Sleep hygiene essentials

• Fixed wake time; morning light; no screens 60–90 minutes before bed; cool, dark, quiet bedroom; caffeine cut-off by early afternoon; alcohol avoidance.

• Stimulus control

• Use the bed only for sleep and intimacy; if awake >20 minutes, leave the bed, do a calm activity, return when drowsy.

• Evening downshifting

• Gentle stretches, diaphragmatic breathing, or a warm bath 1–2 hours before bed to leverage thermoregulation for sleep onset.

• Pain-aware positioning

• Side-lying with pillow support or supine with knees elevated; adjust mattress and pillow ergonomics.

• Dermatology-specific supports

• Nighttime emollients, breathable sleepwear, humidifier if dry air exacerbates itching; coordinate with dermatology for anti-pruritic regimens.

Measuring Progress and Adjusting Care

• Track via sleep diary: sleep latency, WASO, total sleep time, naps.
• Use validated scales: Insomnia Severity Index; if daytime sleepiness concerns arise, add Epworth.
• Review adverse effects at every step; adjust doses and timing accordingly.
• Celebrate small gains—e.g., 15-minute reductions in WASO—as leading indicators of consolidation.

Citations and Evidence Base

This post reflects contemporary insights in sleep regulation and pharmacotherapy, including:

• The primacy of CBT-I as first-line for chronic insomnia (Trauer et al., 2015; Morin & Benca, 2012).
• Safety considerations in older adults and women for sedative-hypnotics (BMJ and NIH/NCBI reviews).
• Efficacy and safer profile of DORAs for sleep maintenance with lower cognitive and motor impairment risks (Krystal, 2019).
• Role of melatonin receptor agonists for onset and circadian support (Arendt, 1998; JAMA).
• Risks of Z-drugs and benzodiazepines in older adults (BMJ sources).
• The physiologic rationale for integrating pain and autonomic modulation with sleep therapies (Saper et al., 2001; Sakurai, 2007).

References

• Arendt, J. (1998). Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Reviews in Endocrine & Metabolic Disorders.
• Baglioni, C., et al. (2011). Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders.
• Besedovsky, L., Lange, T., & Born, J. (2012). Sleep and immune function. Pflugers Archiv.
• Czeisler, C. A., & Gooley, J. J. (2007). Sleep and circadian rhythms in humans. Cold Spring Harbor Symposia on Quantitative Biology.
• Diekelmann, S., & Born, J. (2010). The memory function of sleep. Nature Reviews Neuroscience.
• Espie, C. A., et al. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder. Sleep.
• Goldstein, A. N., & Walker, M. P. (2014). The role of sleep in emotional brain function. Annual Review of Clinical Psychology.
• Iliff, J. J., et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes. Science Translational Medicine.
• Irwin, M. R. (2019). Sleep and inflammation: Partners in sickness and in health. Nature Reviews Immunology.
• Ju, Y.-E. S. et al. (2014). Sleep quality and preclinical Alzheimer disease. JAMA Neurology.
• Krystal, A. D. (2019). Orexin receptor antagonists for insomnia: A new approach. Current Treatment Options in Neurology.
• Morin, C. M., & Benca, R. (2012). Chronic insomnia. The Lancet.
• Morin, C. M., & Espie, C. A. (2003). Insomnia: A Clinical Guide to Assessment and Treatment. Springer.
• Porkka-Heiskanen, T., et al. (1997). Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science.
• Sakurai, T. (2007). The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nature Reviews Neuroscience.
• Saper, C. B., et al. (2001). The neurobiological basis of sleep. Nature.
• Sateia, M. J., et al. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. Journal of Clinical Sleep Medicine.
• Spiegel, K., et al. (1999). Impact of sleep debt on metabolic and endocrine function. The Lancet.
• Tononi, G., & Cirelli, C. (2014). Sleep and the price of plasticity: From synaptic and cellular homeostasis to memory consolidation and integration. Neuron.
• Trauer, J. M., et al. (2015). Cognitive behavioral therapy for chronic insomnia: A systematic review and meta-analysis. Annals of Internal Medicine.
• Walker, M. P., & Stickgold, R. (2006). Sleep, memory, and plasticity. Annual Review of Psychology.
• Xie, L., et al. (2013). Sleep drives metabolite clearance from the adult brain. Science.
• Hirshkowitz, M., et al. (2015). National Sleep FFoundation’ssleep time duration recommendations: methodology and results summary. Sleep Health.

SEO tags: insomnia, sleep physiology, adenosine, melatonin, orexin, histamine, CBT-I, sleep restriction, stimulus control, circadian rhythm, glymphatic system, REM sleep, NREM sleep, integrative chiropractic care, internal medicine, functional medicine, personal injury, rehabilitation, El Paso clinic, Dr. Alexander Jimenez, Dr. Maria Guadalupe Cardenas, patient education, hypnotics, evidence-based sleep care, DORA medications, ramelteon, doxepin, autonomic regulation, breathing for sleep, Mission Plaza Injury Medical Clinic El Paso, Injury Medical Clinic PA